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Abstract
Background: We have raised a panel of broad spectrum neutralizing monoclonal antibodies against the highly pathogenic
H5N1 avian influenza virus, which neutralize the infectivity of, and afford protection against infection by, most of the major
genetic groups of the virus evolved since 1997. Peptide mimics reactive with one of these broad spectrum H5N1
neutralizing antibodies, 8H5, were identified from random phage display libraries.
Method: The amino acid residues of the most reactive 12mer peptide, p125 (DTPLTTAALRLV), were randomly substituted to
improve its mimicry of the natural 8H5 epitope.
Result: 133 reactive peptides with unique amino acid sequences were identified from 5 sub-libraries of p125. Four residues
(2,4,5.9) of the parental peptide were preserved among all the derived peptides and probably essential for 8H5 binding.
These are interspersed among four other residues (1,3,8,10), which exhibit restricted substitution and probably could
contribute to binding, and another four (6,7,11,12) which could be randomly substituted and probably are not essential for
binding. One peptide, V-1b, derived by substituting 5 of the latter residues is the most reactive and has a binding constant
of 3.16610
29 M, which is 38 fold higher than the affinity of the parental p125. Immunoassay produced with this peptide is
specifically reactive with 8H5 but not also the other related broad spectrum H5N1 avian influenza virus neutralizing
antibodies. Serum samples from 29 chickens infected with H5N1 avian influenza virus gave a positive result by this assay
and those from 12 uninfected animals gave a negative test result.
Conclusion: The immunoassay produced with the 12 mer peptide,V1-b, is specific for the natural 8H5 epitope and can be
used for detection of antibody against the broad spectrum neutralization site of H5N1 avian influenza virus.
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Introduction
As defined by conventional serology, the neutralization site of
the influenza A virus encompasses the site located to the head of
the HA molecule, where the virus contacts with host cells to
initiate infection and area in the proximity of it, such that binding
of antibody to this site arrests infection [1]. Antigenic specificity of
the site changes rapidly, enabling the virus to evade host immune
surveillance, thereby resulting in recurrent seasonal outbreaks and
contributing to regular occurrence of influenza pandemics [2,3].
Current effort to control the infection is to predict the antigenic
specificity of the emerging strains on the basis of those circulating
presently and in the past [4,5]. The entailing difficulty is that the
prediction is not always accurate and that vaccines might not be
produced in time.
The recent discovery of a distinct type of broadly cross reacting
and relatively conserved (BCRC) neutralization sites is significant,
because they present an alternative and a more stable target to
control the infection. Identified by monoclonal antibodies instead
of conventional antisera, one of such neutralizing sites, designated
broad spectrum H5N1 neutralizing site [6,7,8], is present in most
of the major genetic groups (clades) of the H5N1 highly
pathogenic avian influenza virus isolated since 1997, when the
latter first re-emerged [2]. The other, the heterosubtypic
neutralizing site, is present in different HA subtypes of influenza
virus [8,9,10]. It is especially significant that co-crystalization of
the heterosubtypic antibody and HA molecules has located the
hetersubtypic neutralizing site to the stem of the HA molecule
[11,12], because this physically separates the newly identified
neutralizing site from the neutralizing site identified by conven-
tional serology [13,14]. It is not known why such BCRC
neutralization sites have escaped detection before. One possible
explanation is that in response to infection or immunization, the
antibodies produced against these BCRC neutralization sites have
been masked by those produced against the dominant antigenic
determinant locating to the head of the HA molecule. The
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neutralization sites were nevertheless found to effectively inhibit
virus mediated hemeagglutination and neutralize infectivity of the
virus and some of them are tested and also found to be efficacious
in treatment of the respective infection even at relatively late stages
of the illness [6]. This shows that the respective epitopes of the
BCRC monoclonal antibodies are potential targets for broad
spectrum immune intervention of influenza.
The H5 cross reacting neutralizing site is identified by a panel of
monoclonal antibodies, which are exclusively reactive against the
H5N1 influenza virus, but not also against other influenza virus
subtypes [6,15]. The antibodies are cross-reacting, mutually
blocking binding of one another to the virus [6]. This suggests
that the respective epitopes are located in proximity of one another
in a single neutralizing site. The nature of the epitope of one of
these antibodies, 8H5, was investigated using 12mer peptide
mimics. The results suggest that 4 amino acid residues
(L2,T4,L5,T9) are essential for binding with 8H5 and since these
residues are located separately on the peptides recognition of
which by the antibody probably depends on the juxtaposition of
these residues on the peptides [16].
Presently, one of the most reactive of the peptides, p125, was
randomly substituted. The amino sequences of the resulting
reactive peptides were analyzed to further investigate the nature of
the native epitope. The most reactive of the derived peptides was
evaluated for use as a surrogate of the natural 8H5 epitope to
detect antibody against the broad spectrum H5N1 neutralizing
site.
Materials and Methods
Virus strains and antibodies
Thirteen murine monoclonal antibodies were used:
8H5,8G9,13D4, 2F2, and 3G4 were raised against H5N1 virus
strains Chicken/HK/YU22/2002 (clade 8) [6]; 8C11,16D7,and
8H3, against a recombinant structural protein of Hepatitis E Virus
[17]; 9B2 and 6D6 against HCV; 18B6,11H10,and 28F10, against
HBV core protein. The H5N1 virus strains, Chicken/HK/YU22/
2002 and Shenzhen/406H/2006, were provided by the State Key
Laboratories of Emerging Infectious Diseases of the Department of
Microbiology of the University of Hong Kong.
Sub-library Construction
The sub-libraries were constructed on the phage vector M13KE
(NEB Ph.D. system, New England Biolabs, Ipswich, Massachu-
setts, USA) according to the standard cloning techniques and M13
manipulation [18]. Oligonucleotide with amino acid substitutions
of different residues of the 12mer peptide, p125, was designed and
synthesized. The universal extension primer was annealed and
extended with library oligonucleotide, and the resulting duplex
was inserted between Acc65I and EagI sites of the vector M13KE.
Sub-libraries were generated after electroporating into the
bacterial strain ER2738.
Affinity Selection of 8H5 mAb binding peptides
Affinity selection of 8H5 mAb binding peptides was performed
according to the previous method [15]. Briefly, an aliquot of 1 ml
of the 12-mer peptide sub-library (containing 2.9610
11 peptide
bound phages) was pre-mixed with 30 ug 8H5 mAb in 200 ul Tris
buffer saline (TBS) with 0.1%Tween-20 for 20 min at room
temperature. Then, 15 ul protein A in blocking buffer (0.1 M
NaHCO3 (pH 8.6) and 5 mg/ml BSA, 0.02% NaN3) were added
to the solution and left to stand for 20 min.The unbound phage
particles were removed and the bound phages were eluted. After
three rounds of screening, the phage clones were analyzed by
phage ELISA and DNA sequencing [16].
Affinity determination
The kinetics of the interaction between 8H5 mAb and peptides
were measured by BIAcore X1000 (BIAcore, Uppsala, Sweden).
Gold-coated CM-5 sensor chips were coated with a carboxylated
dextran polymer matrix with which the protein A was amine
coupled. The first flow cell on the chip was coated with 2800
resonance units (RU) of the protein A, while the other flow cell was
left uncoated and blocked as control. Affinity measurements were
initiated by injecting 8H5 mAb at the concentration of 19 mg/ml.
Then, peptide was added and allowed to bind at 20 ml/min for
2 min. The complex of 8H5 mAb and peptide was eluted by
10 mM HCl for 2 min. Each peptide was tested at five
Table 1. Generation of p125 phage sub-libraries.
Phage Libraries Random substitution
1 Specific Substitutions* Library Diversity 8H5 reactive phage
D
residues residues* amino acids Theoretical Actual Total unique aa sequences
12MH I 3, 5, 7, 10 1.6610
5 1.0610
6 48 10
12MH II 4, 6, 8, 10 3 P, A, Q, E 2.56610
6 4.5610
6 81 14
12MH III 2, 4, 6, 8 3 P, A, Q, E 5.12610
6 6.5610
6 60 16
10 K, R
12MH IV 6, 9, 11 1 D, E,Q 1.02610
6 6.5610
6 94 77
3P , A , Q , E
8A , G
10 K, R
12MH V 1, 3, 6, 7, 12 8 A, G 1.28610
7 1.5610
7 39 16
10 K, R
Total 322 133
1different residues of the 12mer p125 were randomly substituted with 20 aa to generate the successive phage libaries.
*In addition, residues found to exhibit restricted substitution were specifically substituted in generation of the subsequent libraries.
D8H5 reactive phage clones were identified; the peptides were sequenced.
doi:10.1371/journal.pone.0024144.t001
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generated with BIA evaluation 2.1 software using kinetics
simultaneous ka/kd protocols from which the equilibrium
dissociation constant (KD) was calculated.
Peptide competing to H5N1 virus
ELISA plates were coated with 2F2 and 3G4 mAbs (2 ug/ml
respectively). H5N1 virus Chicken/HongKong/YU22/2002
(16HA) or Shenzhen/406H/2006 (16HA) was added to the well
and incubated at 37uC for 1 h. Then the diluted peptide from
50 mg to 0.1 mg and 8H5-HRP (1:500) were simultaneously added
to the well and incubated at 37uC for 1 h. HBcAg synthetic
peptide G1 was used as negative control. TMB (3,39,5,59-
Tetramethylbenzidine) was then added and color intensity was
measured in a microplate reader.
Mimotope ELISA
Two copies of V-1b were inserted to the positions 79 and 80 of
the 1-149 fragment of HBc protein in tandem with the flexible
linker, GGGGS Gene coding for the fusion protein was cloned
into the plasmid pTO-T7 and fusion protein HBc-V-1b was
expressed and purified as described before [19]. The purified
fusion protein was coated on microplate at the concentration of
5 mg/ml. Microplates similarly coated with the carrier HBV core
(HBc) protein was used as negative control.
In the assay of binding specificity with 8H5 mAb, 8H5 mAb was
added to test the reaction with the fusion protein. Other 3 H5-
related mAbs, 3 anti-HEV mAbs, 2 anti-HCV mAbs were used as
negative control. The 8H5 epitope specific ELISA was further
applied to chicken serum. Chicken serum was diluted at 1:500 and
then added to microplate. Rabbit anti-chicken antibody (IgG)
conjugated with HRP (Keygen, China) diluted at 1:10000 was
used as the secondary antibody.
Results
Random substitution of p125
To improve the mimicry of the natural 8H5 epitope by p125,
we generated in succession 5 sub libraries by random substitution
of 3 to 5 residues of the peptide (Table 1). Residues which were
found to exhibit restricted substitutions in one sub library were
specifically substituted with the same amino acids in generating the
subsequent libraries. For example, substitution of residue 3 was
found in the first library (12MH1) to be restricted to P,A,Q and E
and this residue was specifically substituted with the same four aa
in generating the subsequent sub libraries. The diversity of the 5
libraries was similar to the respective theoretical values. Screening
of these libraries yielded 322 phage clones reactive with 8H5.
Sequencing revealed that these reactive clones encompass 133
distinct 12mer peptides.
Table 2 summarizes amino acid substitutions observed among
the 133 distinct p125-related 12mer peptides. Confirming previous
findings [16], the results show that 4 residues (T2,L4,T5,L9) of the
parental p125 were preserved among all the derived peptides,
suggesting that these residues are essential for binding with 8H5.
Another 4 residues, namely residues D1, P3, A8,and R10, exhibit
restricted substitution, suggesting that these residues may affect
8H5 binding. The remaining 4 residues, T6, A7, L11, V12, could
be randomly substituted, suggesting that they may not contribute
to 8H5 binding or minimally so. Thus, the residues involved in
binding are interspersed among residues that apparently do not
participate in binding, suggesting that 8H5 binds to discontinuous
residues on the peptides.
Effects of amino acid substitutions on 8H5 binding
The 8H5 reactivity of the phages displaying p125 and 133
different related 12mer peptides was determined by titration using
microplates previously coated with 8H5 (see Fig. 1). The reactivity
was expressed in 8H5 titer, defined as the phage dilution yielding
an OD value of 1.5 (TOD1 . 5 ). Compared with the 8H5 titer of
parental p125 phage (TOD1 . 5=2.96), the 8H5 reactivity of three
phage clones displaying the peptides III-2a, II-1c and V-1b,
respectively, was variously increased, with 8H5 titers of 3.27, 7.07
and 13.23, respectively (Table 3). The 8H5 titers of the other 130
phage clones was either comparable to that of the parental p125
phage, as exemplified by the phage bearing the peptide IV-1b (TO
D1 . 5=2.76), or lower with TOD1 . 5 ,2.0 (not shown).
The 8H5 reactivity of the 5 peptides was further assessed by
their capacity to block 8H5 from binding with two strains of H5N1
influenza virus. In these experiments, serially diluted aliquots of
Table 2. Amino acid substitution of 8H5-reactive 12mer
peptides.
Residues p125 p125 related peptides (n=133)
1 D D,E,Q
2T T
3 P P,A,Q,E
4L L
5T T
6 T 20 natural aa
7 A 20 natural aa
8A A , G
9L L
10 R K, R
11 L 20 natural aa
12 V 14 natural aa
133 distinct 12mer peptides reactive with 8H5 were identified from 5 sub-libraries
of p125 as described in Table 1.
doi:10.1371/journal.pone.0024144.t002
Figure 1. Titration of phage displaying p125 and related 12mer
peptides. 10
13 phage displaying the p125 or the related 12mer
peptides, V-1b, II-1c, III-2a, IV-1b, and IV-48 was serially diluted and
allowed to react with microplates previously coated with 8H5 for
30 min. The plates were in turn reacted with anti-phage. The 8H5
binding activity of the phage is determined from the titration curves
and expressed as the phage dilution yielding an OD value of 1.5 (TOD1.5).
doi:10.1371/journal.pone.0024144.g001
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aliquots containing indicated amounts of synthetic peptide or HBcAg
synthetic peptide (G1) were allowed to react with 8H5. The residual
antibody available for virus binding with 2 strains of H5N1 was
determined by ELISA. 8H5 blocking activity of peptides is expressed as
blocking dose, defined as the amount of peptide that reduces 8H5
binding by 50%.
doi:10.1371/journal.pone.0024144.g002
Figure 3. Evaluation of ELISA produced with the 8H5
reactive12mer peptide (V-1b). In the top panel, microplates were
coated with V-1b-HB core antigen (HBc-V-1b) were reacted with
monoclonal antibodies specific for H5 molecule of H5N1 avian influenza
virus (H5 mAbs), hepatitis E virus (HEV mAbs), hepatitis C virus (HCV
mAb) and monoclonal antibodies specific for the HBV core antigen
(HBV mAbs). In the bottom panel, these and also microplates coated
with HBc alone were reacted with serum samples from 29 chicken
infected with the H5N1 avian influenza virus and 8 control uninfected
animals.
doi:10.1371/journal.pone.0024144.g003
Table 3. 8H5 reactivity and dissociation constants of p125 and related 12mer peptides.
Peptide Amino acid substitutions
{ Titer
{ Blocking Dose* Kd
1
(Tod1.5) Yu22 SZ/406H (MOLAR)
p125 2.96 18.34 ug 11.16 ug 8.24E-07
IV-1b D1E, P3E,R10K (T6I, L11Y) 2.76 .50 ug .50 ug 9.80E-07
III-2a P3E (T6K, A7Q) 3.27 15.19 ug 6.10 ug 2.84E-08
II-1c A8G, R10K (T6I) 7.07 8.90 ug 2.38 ug 1.15E-08
V-1b D1E, A8G, R10K (T6I, V12K) 13.23 5.70 ug 2.31 ug 3.16E-09
{Residues which could be randomly substituted shown in parenthesis.
{The 8H5 reactivity of phage bearing p125 and the related 12mer peptides was determined by titration as in Figure 1 and expressed in titer defined as the phage dilution
yielding an OD value of 1.5 (Tod1.5).
*8H5 reactivity of the respective peptides was determined as in Figure 2 and expressed in blocking dose, defined as amount of the peptide that block binding of 8H5 to the
indicated strain of the H5N1 avian influenza virus by 50%.
1Affinity of the peptides for 8H5 was determined by surface plasma resonance using BiaCore and expressed as dissociation constant (Kd).
doi:10.1371/journal.pone.0024144.t003
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residual antibody available for binding with the viruses was
determined by ELISA (Fig. 2). 8H5 reactivity of the peptides was
expressed in 8H5 blocking dose, which is defined as the amount of
the peptide that blocks 8H5 binding by 50%.
The affinity of the peptides for 8H5 was also determined by
surface plasma resonance using BiaCORE. Table 3 relates the
amino acid substitutions of the p125 related peptides with their
respective 8H5 reactivity and affinity for the antibody. The results
show that V-1b is the most reactive with 8H5 and has the highest
affinity for the antibody and suggest that this is probably attributed
to the substitutions, D1E, A8G and R10K. The peptide also
contains two other substitutions, T6I and V12K, but since both
residues could be randomly substituted, they are unlikely to affect
the 8H5 reactivity of the peptide or its affinity for the antibody.
Two other peptides, II-1c and III-2a, exhibit a moderate increase
in 8H5 reactivity and affinity for the antibody and this is probably
attributed to A8G and R10K, in the case of the peptide II-1c, and
to P3E, in the case of the III-2a peptide. On the other hand, the
8H5 reactivity of IV-1b and its affinity for the antibody was lower
than the parental p125 and this is probably attributed to D1E, P3E
and R10K. II-1c, III-2a and IV-1b also variously contain
substitutions at residues T6, A7 L11 and V12, which are
considered unlikely to affect 8H5 binding.
8H5 epitope specific ELISA
An enzyme-linked immunosorbant assay (ELISA) was produced
with V-1b fused to the hepatitis B virus core antigen (HBcAg). The
antigenic specificity of the assay was assessed against 8H5, other
control monoclonal antibodies and serum samples from chicken
previously infected or not with H5N1 virus (Fig. 3). The results
show that the assay is exclusively specific for 8H5. Apart from the
monoclonal antibodies generated against the carrier protein, the
assay exclusively binds 8H5, but not also the other related broad
spectrum H5N1 avian influenza neutralizing antibodies or the
unrelated control antibodies raised against HEV and HCV,
respectively (upper panel). The chicken serum samples were
obtained from a poultry farm in southern China and included 29
which were previously tested to be reactive for H5N1 avian
influenza virus and 8 which are seronegative for the virus (Chen Y,
PhD thesis 2010, Xiamen University, China). The results show
that only the H5N1 avian influenza reactive samples were also
8H5 reactive (lower panel).
Discussion
We have derived a 12mer peptide, V1-b, from phage display
libraries, which closely mimics the natural epitope of the broad
spectrum H5N1 avian virus neutralizing monoclonal antibody,
8H5. ELISA produced with this peptide is specific for the antibody
and serves to distinguish between serum samples from chicken
which had and had not been previously infected with H5N1 avian
Influenza virus. This suggests that this peptide could be used as a
surrogate of the natural 8H5 epitope to detect antibody against the
broad spectrum neutralization site of the H5N1 avian influenza
virus in serum samples.
We generated in succession 5 phage display libraries by
systematically substituting different residues of p125 and analyzing
the aa sequences of 133 8H5 reactive peptides thus derived.
Involvement of each residue in binding with the antibody was
assessed according to its susceptibility to substitution. Confirming
earlier findings [6] the residues T2,L4,T5,L9 of the parental p125
were considered to be essential for antibody binding, because they
were conserved among all the reactive peptides. It was further
shown that these residues were interspersed among 4 other
residues (D1, P3, A8, R10), which may contribute to antibody
binding, because they exhibited restricted patterns of substitution
and another 4 (T6, A7, L11, V12), which may not involved in
antibody binding, because they could be randomly substituted.
Titration of 8H5 binding activity found that the most of the
peptides were either less or similarly reactive as the parental p125,
except for 3 which are more reactive than p125. The peptide V1-b
is the most reactive of the latter, showing the highest level of 8H5
binding and capacity to block the antibody from binding with
H5N1 avian influenzavirus. The affinity of this peptide for 8H5
was found by plasma surface resonance to be 3.16610
9 M, 38
time that of the parental p125. ELISA produced with this peptide
shows that it binds exclusively with 8H5 and not also the cross-
reacting broad spectrum H5N1 neutralizing antibodies The
peptide was reactive with serum samples from chickens infected
with H5N1 avian influenza virus, but not also the samples from
control uninfected animal. Consistent with findings by co-crystal-
ization of a heterosubtypic antibody and HA molecule [6], V1-b
was aligned to amino acid residues 44, 77, 267, 268, 277, 281,
297–302 locating to the stem of the HA molecule, using the
Pepsurf software (http://pepitope.tau.ac.il/).
Peptide mimics have been used as surrogates of the natural
epitopes for diagnosis [20,21,22] and vaccines [23,24,25] and
treatment [23,26,27]. The present findings show that the 12 mer
peptide, V1-b, closely mimics the natural 8H5 epitope, to the
extent that it could be used as surrogate of the natural epitope in
an objective ELISA assay to detect antibody against the broad
spectrum H5N1 avian Influenza virus neutralization site in serum
samples.
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